IL HJR0035

Urges U.S. Congress to include provisions in biosimilar drug legislation ensuring adequate testing to protect public health and maintain physician control over patient treatment decisions

Requests federal legislation preserve physician discretion in prescribing biosimilar products, recognizing they are not chemically or therapeutically identical to original biologic drugs

Calls for federal law to maintain financial incentives for innovation in biotechnology drug discovery and development

Directs delivery of the resolution to all members of Illinois' congressional delegation